Continuing this research, Chauvin et al. indicated that the simultaneous blockade of TIGIT and PD-1 should be considered as a means of achieving a strong antitumor response of CD8+ T cells in patients with advanced melanoma [54]. This evidence concerns the gene CD8A and melanoma.